Author | PET timing | Parameter | DFS | OS |
---|---|---|---|---|
Akimoto [12] | After completion | %ΔSUVmax > 80 | N/S for TN or HER2+ | NR |
 |  | SUVmax ≤ 1.3 | P = 0.026 for TN or HER2+ | NR |
Champion [13] | After 3 cycles | %ΔSUVmax | N/S | N/S |
 | After completion | %ΔSUVmax > 72 | P = 0.05* Adjusted P = 0.01* | N/S |
Chen [14] | During or after | Mid- or post-SUVmax†| HR = 1.13 (1.06–1.21) Adjusted HR = 1.09 (1.01–1.17) | HR = 1.16 (1.08–1.24) Adjusted HR = 1.14 (1.06–1.23) |
 |  | Mid- or post-SUVmax < 2.5 | HR = 0.28 (0.13–0.62) | HR = 0.25 (0.11–0.60) |
 |  | %ΔSUVmax†| N/S | N/S |
Dunnwald [15] | At mid-therapy | Log2(SUVpeak)†| N/S | HR = 1.96 (1.14–3.34) Adjusted HR = N/S |
 |  | Δ%SUVpeak†| N/S | HR = 0.72 (0.54–0.96) Adjusted HR = N/S |
Emmering [16] | After completion | CMR | HR = 0.24 (0.08–0.79) Adjusted HR = 0.28 (0.08–0.96) | N/S |
Garcia Vicente [17] | After 2 cycles | CMR-tumour | N/S | N/S |
 |  | %Δtumour-SUVmax ≥ 62 | N/S | N/S |
 |  | CMR-lymph node | N/S | N/S |
 | After completion | CMR-tumour | N/S | N/S |
 |  | CMR-lymph node | P = 0.003 Adjusted P = N/S | P = 0.016 Adjusted P = N/S |
 |  | Tumour-SUVmax | < 1.05: HR = 0.06 (0.01–0.47) | < 1.15: N/S |
 |  | Lymph node-SUVmax | < 1.30: N/S | < 0.40: N/S |
 |  | %Δtumour-SUVmax | ≥ 74: N/S | ≥ 84: N/S |
Groheux [18] | After 2 cycles | SUVmax < 7.4 | P = 0.011 | NR |
 |  | %ΔSUVmax ≥ 12 | P = 0.033 | NR |
 |  | TLG < 30.5 | P = 0.017 | NR |
 |  | %ΔTLG ≥ 51 | P < 0.001 | NR |
Groheux [19] | After 2 cycles | %ΔSUVmax†| HR = 0.86 (0.78–0.94) Adjusted P = 0.004 | NR |
 |  | %ΔSUVmax | P = 0.021 and P = 0.028‡ | NR |
Humbert [20] | After 1 cycle | %ΔSUVmax ≥ 16 | HR = 0.19 (0.06–0.64) | HR = 0.09 (0.02–0.54) |
Humbert [21] | After 1 cycle | %ΔSUVmax ≥ 50% | N/S | N/S |
Hyun [22] | After completion | Log2(SUVmax)†| HR = 1.86 (1.38–2.51) Adjusted HR = 1.51 (1.04–2.19) | NR |
 |  | %ΔSUVmax†| HR = 0.98 (0.97–0.99) Adjusted HR = 0.99 (0.98–1.00) | NR |
 |  | Log2(MTV)†| HR = 1.26 (1.15–1.38) Adjusted HR = 1.14 (1.01–1.27) | NR |
 |  | %ΔMTV†| HR = 0.99 (0.99–1.00) Adjusted HR = 1.00 (0.99–1.00) | NR |
Ishiba [23] | After completion | SUVmax ≤ 1.7 | P = 0.004 Adjusted P = 0.014 | P = 0.01 Adjusted P = 0.029 |
Jung [24] | After completion | Δ%SUVpeak ≥ 84.8 | P = 0.04 Adjusted P = N/S | NR |
Kim [25] | After completion | SUVmax†| HR = 1.20 (1.12–1.28) | NR |
 |  | MTV†| HR = 1.02 (1.01–1.03) | NR |
 |  | TLG†| HR = 1.00 (0.99–1.00) | NR |
 |  | %ΔSUVmax†| HR = 0.99 (0.98–0.99) | NR |
 |  | %ΔMTV†| HR = 1.00 (0.99–1.00) Adjusted HR = 0.99 (0.98–1.00) | NR |
 |  | %ΔMTV > 90.7 | HR = 0.39 (0.19–0.79) | NR |
 |  | %ΔTLG†| HR = 0.99 (0.99–1.00) | NR |
Kitajima [26] | After completion | CMR | HR = 0.15 (0.02–0.70) Adjusted HR = N/S | NR |
Kiyoto [27] | After completion | %ΔSUVmax > 15.9 | HR = 0.18 (0.05–0.88) | NR |
Kolesnikov-Gauthier [28] | After 1 cycle | %ΔSUVmax > 15 | 4-year DFS: 85% vs. 44%, P = 0.008 | N/S |
Lee [29] | After 3 cycles | %ΔSUVmax > 66.4 | P < 0.001 | P = 0.009 |
 |  | %ΔSUVmax†| HR = 0.97 (0.95–0.98) Adjusted HR = 0.97 (0.95–0.99) | HR = 0.98 (0.96–0.99) Adjusted HR = 0.97 (0.95–0.99) |
Lian [30] | After 2 cycles | CMR | HR = 0.17 (0.04–0.73) Adjusted HR = 0.04 (0.00–0.42) | NR |
Lim [31] | After 1 cycle | %ΔSUVmax > 41 | P < 0.001 Adjusted HR = 0.13 (0.03–0.49) | NR |
Zucchini [32] | After 2 cycles | %ΔSUVmax > 50 | N/S for all P = 0.049 for ER+/HER2− | NR |